Drug Approval Marks Another Win for Merck KGaA’s Rare Tumor Strategy
Posted
Frank Vinluan (via MedCity News)
Merck KGaA drug Pimjetmi is now FDA approved for treating tenosynovial giant cell tumor. This drug complements other rare tumor assets the Germany-based drugmaker has acquired in a series of business deals.
The post Drug Approval Marks Another Win for Merck KGaA’s Rare Tumor Strategy appeared first on MedCity News.
